MedTrace Logo

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

NCT00353756 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2006-10-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.

Conditions

Interventions

DRUG

C326, IL-6 Inhibitory Avimer protein

Sponsors & Collaborators

  • Avidia

    lead INDUSTRY

Principal Investigators

  • Lee Min Yap, MD · Alfred Hospital, Melbourne, Australia

  • Graham Radford-Smith, MD · Royal Brisbane and Womens Hospital, Brisbane, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353756 on ClinicalTrials.gov